Comparison of clinical efficacy between ultra-LABAs and ultra-LAMAs in COPD: a systemic review with meta-analysis of randomized controlled trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Eun Yeong | - |
dc.contributor.author | Kim, Se Yong | - |
dc.contributor.author | Kim, Min-Ji | - |
dc.contributor.author | Kim, Seonwoo | - |
dc.contributor.author | Park, Dong Ah | - |
dc.contributor.author | Yoo, Kwang Ha | - |
dc.contributor.author | Park, Yong Bum | - |
dc.contributor.author | Hwang, Yong Il | - |
dc.contributor.author | Rhee, Chin Kook | - |
dc.contributor.author | Jung, Ji Ye | - |
dc.contributor.author | Lee, Hyun | - |
dc.contributor.author | Park, Hye Yun | - |
dc.date.accessioned | 2021-07-30T05:00:51Z | - |
dc.date.available | 2021-07-30T05:00:51Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2018-12 | - |
dc.identifier.issn | 2072-1439 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/2652 | - |
dc.description.abstract | Background: A single long-acting bronchodilator, ultra-long acting muscarinic antagonist (ultra-LAMA) or ultra-long acting β2-agonist (ultra-LABA) is preferred for the initial treatment of patients with chronic obstructive pulmonary disease (COPD); however, there are few head-to-head comparative studies between the two. Here, a meta-analysis of randomized controlled trials was performed to compare the clinical efficacy between ultra-LABA and ultra-LAMA in patients with moderate-to-severe COPD. Methods: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched (to March 1, 2017) to identify all published randomized controlled trials. Results: Of the 12,906 articles found by searching the databases, we obtained data from 10,591 patients with COPD (LABA, n=5,058; LAMA, n=5,533) in seven published studies. Our results showed that COPD exacerbation were significantly lower in patients taking ultra-LAMA than those taking ultra-LABA (odds ratio =0.857, P=0.0008). However, no significant differences were observed between ultra-LAMA and ultra-LABA patients regarding improvement in trough forced expiratory volume in 1 s, the transitional dyspnea index, or St. George’s Respiratory Questionnaire score. Conclusions: This study suggests that COPD exacerbation occurred less often in patients taking an ultra-LAMA than in those taking an ultra-LABA with similar efficacy of lung function and quality of life. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AME PUBL CO | - |
dc.title | Comparison of clinical efficacy between ultra-LABAs and ultra-LAMAs in COPD: a systemic review with meta-analysis of randomized controlled trials | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Hyun | - |
dc.identifier.doi | 10.21037/jtd.2018.11.50 | - |
dc.identifier.scopusid | 2-s2.0-85059542332 | - |
dc.identifier.wosid | 000456834700055 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THORACIC DISEASE, v.10, no.12, pp.6522 - 6530 | - |
dc.relation.isPartOf | JOURNAL OF THORACIC DISEASE | - |
dc.citation.title | JOURNAL OF THORACIC DISEASE | - |
dc.citation.volume | 10 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 6522 | - |
dc.citation.endPage | 6530 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.subject.keywordPlus | OBSTRUCTIVE PULMONARY-DISEASE | - |
dc.subject.keywordPlus | ONCE-DAILY INDACATEROL | - |
dc.subject.keywordPlus | ACUTE EXACERBATION | - |
dc.subject.keywordPlus | TIOTROPIUM | - |
dc.subject.keywordPlus | ANTAGONISTS | - |
dc.subject.keywordPlus | SALMETEROL | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | DECLINE | - |
dc.subject.keywordPlus | MODEL | - |
dc.subject.keywordAuthor | Chronic obstructive pulmonary disease (COPD) | - |
dc.subject.keywordAuthor | ultra-long acting beta(2)-agonist (LABA) | - |
dc.subject.keywordAuthor | ultra-long-acting muscarinic antagonist (LAMA) | - |
dc.subject.keywordAuthor | meta-analysis | - |
dc.identifier.url | https://jtd.amegroups.com/article/view/25541/19432 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.